Covaxin, Zydus Cadilla and Oxford-Astra Zeneca’s vaccine development in India remained as a ray of hope to citizens amid trouble times. A lot of review and approval processing became a barrier in delivering the efficacy and safety data to the public.
In this regard, Prime Minister Narendra Modi earlier chaired a virtual meeting with chief ministers and other high rank officers of states and Union Territories on to discuss India’s COVID-19 vaccine distribution strategy and its emergency authorisation on 24th. This was further added with the evaluation process by Modi, which is scheduled to occur on 28th of this month in Hyderabad.
This occurs during the time when multiple drug makers have declared positive results from clinical trials for their COVID-19 vaccine candidates, while Indian vaccine candidate results are yet to be announced. Yesterday, third phase trials commenced at AIIMS. Modi will be visiting Hyderabad as part of three city tour that comprises Ahmedabad and Pune.
After ZyCV-D developed by Zydus Cadilla at Ahmedabad and Oxford-AstraZeneca’s vaccine at Serum Institute at Pune is reviewed, PM will arrive at Hakimpet Air Force station on Saturday afternoon. He will head to Bharat Biotech at Genome valley and spend some time to understand the vaccine development process.